N-(2,5-dichlorophenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(2,5-dichlorophenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
• 英文别名: N-(2,5-dichlorophenyl)-2-oxo-1H-benzo[cd]indole-6-sulfonamide
• 化学式: C₁₇H₁₀Cl₂N₂O₃S
• 分子量: 393.2
• InChiKey: ISJCFPXBLGEWLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• SMALL MOLECULE INHIBITORS AGAINST WEST NILE VIRUS REPLICATION
  申请人：Gu Baohua

  公开号：US20100075993A1

  公开（公告）日：2010-03-25

  The invention provides flavivirus replication inhibitors of WNV and other flaviviruses, such as, for example, JEV, SLEV, AV, KV, JV, CV, YV, TBEV, DENV-1, DENV-2, DENV-3, DENV-4, YFV and MVEV. The invention further provides pharmaceutical compositions including one or more such flavivirus replication inhibitors. The invention further provides methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with flavivirus replication including administering one or more such inhibitors or pharmaceutical compositions.
• [EN] SMALL MOLECULE INHIBITORS AGAINST WEST NILE VIRUS REPLICATION<br/>[FR] INHIBITEURS A PETITES MOLECULES CONTRE LA REPLICATION DU VIRUS DU NIL OCCIDENTAL
  申请人：PHILADELPHIA HEALTH & EDUCATIO

  公开号：WO2007005541A2

  公开（公告）日：2007-01-11

  (EN) The invention provides flavivirus replication inhibitors of WNV and other flaviviruses, such as, for example, JEV, SLEV, AV, KV, JV, CV, YV, TBEV, DENV-1, DENV-2, DENV-3, DENV-4, YFV and MVEV. The invention further provides pharmaceutical compositions including one or more such flavivirus replication inhibitors. The invention further provides methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with flavivirus replication including administering one or more such inhibitors or pharmaceutical compositions.(FR) L'invention concerne des inhibiteurs de réplication de flavivirus du virus du Nil occidental et d'autres flavivirus, tels que JEV, SLEV, AV, KV, JV, CV, YV, TBEV, DENV-1, DENV-2, DENV-3, DENV-4, YFV et MVEV. L'invention se rapporte en outre à des compositions pharmaceutiques comprenant un ou plusieurs des inhibiteurs de réplication de flavivirus précités. L'invention porte sur des procédés de traitement, de prévention, d'inhibition ou d'amélioration d'une ou plusieurs maladies associées à la réplication des flavivirus, qui consistent à administrer au moins l'un des inhibiteurs ou compositions pharmaceutiques précités.